Lifeboat Foundation

Goldman Sachs is taking aim at the world’s biggest quant hedge funds.

The investment bank recently approved a three-year plan to spend more than $100 million to overhaul its stock trading platform, according to Mike Blum, a Goldman partner and chief technology officer of electronic trading.

The project, named Atlas after the Greek God, is meant to accelerate the shift Goldman has been making since realizing in 2014 it was falling behind in Wall Street’s equities technological arms race. Huge quant funds like Renaissance Technologies and Two Sigma are among the most demanding of clients from a technology perspective, and competitors including Morgan Stanley and J.P. Morgan have been jockeying to serve these money managers.

Lux Capital, a New York-based venture capital firm, has raised more than $1 billion across two new funds to back companies on “the cutting edge of science.” The firm raised $500 million for its sixth flagship early-stage fund and another $550 million for an opportunity fund focused on growth-stage investments. Limited partners include global foundations, university endowments, and tech billionaires.

Lux also announced a new hire: Deena Shakir, formerly of GV (Google Ventures), has joined as an investment partner.

To the regular person, Lux’s investments are considered moonshot. The firm has backed entrepreneurs that are working on everything from neurostimulation to nuclear energy to synthetic biology. During my last interview with co-founder and managing partner Josh Wolfe, I actually called one of his portfolio companies “freaking crazy.”

Cell freezing (cryopreservation)—which is essential in cell transfusions as well as basic biomedical research—can be dramatically improved using a new polymeric cryoprotectant, discovered at the University of Warwick, which reduces the amount of ‘anti-freeze’ needed to protect cells.

The ability to freeze and store cells for cell-based therapies and research has taken a step forward in the paper “A synthetically scalable poly(ampholyte) which dramatically Enhances Cellular Cryopreservation.” published by the University of Warwick’s Department of Chemistry and Medical School in the journal Biomacromolecules. The new polymer material protects the cells during freezing, leading to more cells being recovered and less solvent-based antifreeze being required.

Cryopreservation of cells is an essential process, enabling banking and distribution of cells, which would otherwise degrade. The current methods rely on adding traditional ‘antifreezes’ to the cells to protect them from the cold stress, but not all the cells are recovered and it is desirable to lower the amount of solvent added.

The financial-technology boom that turned China into the world’s biggest market for electronic payments is now changing how banks interact with companies that drive most of the nation’s economic growth. As MYbank and its peers crunch reams of new data from payment systems, social media and other sources, they’re growing more comfortable with smaller borrowers that they previously shunned in favor of state-owned giants.

Jack Ma’s online bank is leading a quiet revolution in the way China lends to small businesses, taking aim at a credit bottleneck that has held back Asia’s largest economy for decades.

Using real-time payments data and a risk-management system that analyzes more than 3,000 variables, Ma’s four-year-old MYbank has lent 2 trillion yuan ($290 billion) to nearly 16 million small companies. Borrowers apply with a few taps on a smartphone and receive cash almost instantly if they’re approved. The whole process takes three minutes and involves zero human bankers. The default rate so far: about 1%.

Continue reading “Jack Ma’s $290 Billion Loan Machine Is Changing Chinese Banking” »

César Pelli, the architect whose firm designed Salesforce Tower in San Francisco, the Petronas Twin Towers in Malaysia and other of the world’s most recognizable buildings, died on Friday at his home in New Haven. He was 92.

The Argentine state news agency Telam confirmed the death, as did Anibal Bellomio, a senior associate architect at Pelli’s firm in Connecticut, with news organizations. Mr. Pelli had been dean of the Yale School of Architecture there, from 1977 to 1984.

Mr. Pelli’s many distinctive works include the World Financial Center in New York (now Brookfield Place), famous for its glass-roofed Winter Garden; the Pacific Design Center in Los Angeles, known for its bright blue-glass facade; and a terminal at Washington’s Reagan National Airport. He won hundreds of awards, including the American Institute of Architects’ 1995 gold medal.

The Longevity industry will dwarf all other industries in both size and market capitalization and will require unprecedented sophistication in its approach for assessment and forecasting from the start to neutralize challenges and manifest opportunities

The Longevity Industry is not just about biotechnology and biomedicine. Rather, it consists of several distinct segments: Geroscience, Biomedicine, AgeTech and Finance. Despite this seemingly clear market segmentation, many of these sectors intersect with various domains of science and technology, such as advanced biomedicine, preventive medicine, digital health, AI, financial systems, pension systems and government national strategies.

One of the biggest challenges in assessing the Longevity industry is the extreme broadness of the sector. Hundreds of sectors, industries and domains of science and technology must be analyzed in order to obtain a concrete and comprehensive understanding of the dynamics, trends and direction of the industry. This situation is entirely unique to the Longevity industry. Due to this extreme level of complexity, realistic assessment and forecasting is extremely challenging, and the methods currently being applied for assessment of the biotech and biomedical industries are completely inadequate.

To finance the containment structure, the EBRD managed a fund with contributions from 45 countries, the European Union, and the bank’s own resources. Ukraine contributed 100 million euros (about $112 million).

Deputy project manager Victor Zalizetskyi, who has been part of construction and repairs at the Chernobyl plant since 1987, said he was “filled with pride” that he got to work on a job “that has such a big importance for all humankind.”

However, Zalizetskyi expressed concern in an interview last week that war-torn Ukraine might struggle to cover the maintenance costs for the reactor’s new enclosure. He noted that costly and complicated work such as dismantling unstable sections of the power plant still needs to be done.

The Life Extension Advocacy Foundation, a nonprofit organization dedicated to promoting healthy longevity and aging research through crowdfunding and advocacy initiatives, is hosting its second annual scientific conference, Ending Age-Related Diseases: Investment Prospects and Advances in Research, at the Cooper Union in New York City on July 11th-12th.

The goal of this conference is to promote collaboration between academia, biotech companies, investors, regulators, public health advocates, and doctors in order to foster the creation of interventions to relieve our aging society from the burden of age-related diseases. It is supported by Genome Protection Inc., which is developing therapies to counteract harmful viral elements in our genome that provoke chronic inflammation, and Icaria Life Sciences Inc., which provides contract research in the field of geroscience.

The morbidity from chronic age-related diseases is increasing proportionally to the aging of the global population, representing a challenge to social protection and healthcare systems around the world. The development of next-generation drugs and therapies that could directly target the processes of aging to more effectively prevent and cure age-related diseases has now become a priority, yet the industry is clearly facing unique financial, development, and regulatory bottlenecks.